## REIMBURSEMENT BY DRUG PROGRAMME TYPE IN POLAND ESTIMATES TO 2015

*Appendix. 1. Reimbursement by drug programme type in Poland estimates to 2015, [USD].*

| Lp. | Number of drug program | Name of drug program | Type | Values of reimbursement realised by the NHF, [USD] |
|-----|------------------------|----------------------|------|-----------------------------------------------|
| 1   | B.9.                   | Treatment of breast cancer | oncological | 78,485,573                                     |
| 2   | B.29.                  | Treatment of multiple sclerosis | non-oncological | 54,647,054                                     |
| 3   | B.2.                   | Treatment of chronic viral hepatitis C | non-oncological | 38,244,466                                     |
| 4   | B.10.                  | Treatment of renal cell carcinoma | oncological | 33,328,329                                     |
| 5   | B.14.                  | Chronic myeloid leukemia | oncological | 31,779,778                                     |
| 6   | B.54.                  | Lenalidomide in the treatment of refractory or relapsed multiple myeloma | oncological | 28,788,394                                     |
| 7   | B.71.                  | Interferon-free treatment of chronic viral hepatitis C | non-oncological | 28,727,888                                     |
| 8   | B.4.                   | Treatment of advanced colorectal cancer | oncological | 27,788,808                                     |
| 9   | B.33.                  | Treatment of rheumatoid arthritis and aggressive juvenile idiopathic arthritis | non-oncological | 27,346,493                                     |
| 10  | B.3.                   | Treatment of gastrointestinal stromal tumours (GIST) | non-oncological | 21,902,549                                     |
| 11  | B.1.                   | Treatment of chronic viral hepatitis B | non-oncological | 21,200,573                                     |
| 12  | B.36.                  | Treatment of beneficiaries with severe active ankylosing spondylitis with TNF alfa inhibitors | non-oncological | 18,834,410                                     |
| 13  | B.31.                  | Treatment of pulmonary arterial hypertension (PAH) | non-oncological | 18,695,466                                     |
| 14  | B.59.                  | Treatment of melanoma of skin or mucosal melanoma | oncological | 17,534,442                                     |
| 15  | B.12.                  | Treatment of malignant lymphomas | oncological | 16,893,316                                     |
| 16  | B.48.                  | Treatment of skin melanoma | oncological | 15,093,385                                     |
| 17  | B.46.                  | Treatment of multiple sclerosis after first line treatment failure or rapidly evolving severe multiple sclerosis | non-oncological | 12,716,300                                     |
| 18  | B.23.                  | Treatment of Gaucher's disease | non-oncological | 11,937,381                                     |
| Lp. | Number of drug program | Name of drug program                                                                 | Type                  | Values of reimbursement realised by the NHF, [USD] |
|-----|------------------------|---------------------------------------------------------------------------------------|-----------------------|-----------------------------------------------|
| 19  | B.6.                   | Treatment of non-small cell lung cancer                                                | oncological           | 10 367 449                                   |
| 20  | B.35.                  | Treatment of aggressive psoriatic arthritis                                            | non-oncological       | 9 335 776                                    |
| 21  | B.25.                  | Treatment of mucopolisaccharosis type II (Hunter syndrome)                             | non-oncological       | 9 109 280                                    |
| 22  | B.15.                  | Haemorrhages prevention in children with haemophilia A and B                           | non-oncological       | 8 863 718                                    |
| 23  | B.22.                  | Treatment of Pompe disease                                                             | non-oncological       | 7 973 901                                    |
| 24  | B.32.                  | Treatment of Crohn’s disease (CD)                                                     | non-oncological       | 7 751 211                                    |
| 25  | B.56.                  | Treatment of castration-resistant prostate cancer                                       | oncological           | 7 642 649                                    |
| 26  | B.39.                  | Treatment of secondary hyperparathyroidism in haemodialysis patients                   | non-oncological       | 7 641 937                                    |
| 27  | B.40.                  | Prevention of respiratory syncytial virus infections                                   | non-oncological       | 5 777 221                                    |
| 28  | B.19.                  | Treatment of dwarf children with somatotropin pituitary insufficiency                  | non-oncological       | 5 688 023                                    |
| 29  | B.44.                  | Treatment of severe ige-dependent allergic asthma with omalizumab                      | non-oncological       | 5 313 629                                    |
| 30  | B.50.                  | Treatment of patients with advanced ovarian cancer                                     | oncological           | 5 179 768                                    |
| 31  | B.8.                   | Treatment of soft tissue sarcomas                                                      | oncological           | 3 674 907                                    |
| 32  | B.47.                  | Treatment of moderate and severe plaque psoriasis                                      | non-oncological       | 3 646 576                                    |
| 33  | B.67.                  | Treatment with immunoglobulin transfusions in neurologic diseases                     | non-oncological       | 3 473 645                                    |
| 34  | B.24.                  | Treatment of Hurler disease                                                            | non-oncological       | 2 898 332                                    |
| 35  | B.5.                   | Treatment of hepatocellular carcinoma                                                 | oncological           | 2 525 210                                    |
| 36  | B.62.                  | Treatment of primary immune deficiency (PID) in adult patients                         | non-oncological       | 2 361 726                                    |
| 37  | B.28.                  | Treatment of focal dystonia and hemifacial spasm                                       | non-oncological       | 2 140 716                                    |
| 38  | B.17.                  | Treatment of primary immunodeficiency in children                                      | non-oncological       | 2 023 049                                    |
| 39  | B.26.                  | Treatment of mucopolysaccharidosis type IV (Maroteaux-Lamy syndrome)                   | non-oncological       | 1 756 214                                    |
| 40  | B.58.                  | Treatment of advanced gastric cancer                                                  | oncological           | 1 483 182                                    |
| 41  | B.70.                  | Treatment of neovascular (exudative) form of age-related macular degeneration (AMD)   | non-oncological       | 1 220 918                                    |
| 42  | B.53.                  | Treatment of well-differentiated neuroendocrine pancreatic carcinoma                  | oncological           | 1 163 269                                    |
| 43  | B.20.                  | Treatment of dwarf children with severe primary igf-I deficiency                       | non-oncological       | 1 065 371                                    |
| Lp. | Number of drug program | Name of drug program                                                                 | Type               | Values of reimbursement realised by the NHF, [USD] |
|-----|------------------------|---------------------------------------------------------------------------------------|--------------------|---------------------------------------------------|
| 44  | B.42.                  | Treatment of dwarf children with Turner syndrome (TS)                                 | non-oncological    | 1 043 551                                         |
| 45  | B.68.                  | Treatment of pulmonary arterial hypertension with sildenafil, epoprostenol and macitentan (PAH) | non-oncological    | 1 009 212                                         |
| 46  | B.60.                  | Treatment of Gaucher’s disease type 1                                                 | non-oncological    | 996 794                                           |
| 47  | B.37.                  | Treatment of anaemia in the course of chronic renal insufficiency                      | non-oncological    | 917 417                                           |
| 48  | B.55.                  | Treatment of patients with ulcerative colitis                                         | non-oncological    | 897 512                                           |
| 49  | B.57.                  | Treatment of upper limb spasticity after stroke with botulinum toxin type A           | non-oncological    | 877 637                                           |
| 50  | B.65.                  | Treatment of Philadelphia chromosome-positive (Ph+) chronic acute lymphoblastic leukemia with dasatinib | oncological        | 794 456                                           |
| 51  | B.30.                  | Treatment of spasticity in cerebral palsy                                             | non-oncological    | 780 659                                           |
| 52  | B.27.                  | Treatment of chronic lung infections in beneficiaries with mucoviscidosis              | non-oncological    | 650 177                                           |
| 53  | B.69.                  | Treatment with paricalcitol of secondary hyperparathyroidism in haemodialysis patients | non-oncological    | 512 270                                           |
| 54  | B.49.                  | Oral treatment of iron overload states in the body                                    | non-oncological    | 511 029                                           |
| 55  | B.66.                  | Treatment with bexarotene of mycosis fungoides or Sézary syndrome                     | non-oncological    | 427 935                                           |
| 56  | B.18.                  | Treatment of premature sexual maturation in children                                  | non-oncological    | 367 710                                           |
| 57  | B.52.                  | Treatment of squamous cell cancer of head and neck in combination with radition therapy in locally advanced disease | oncological        | 365 720                                           |
| 58  | B.72.                  | Treatment of melanoma with combination therapy with dabrafenib and trametinib         | oncological        | 315 583                                           |
| 59  | B.63.                  | Treatment of non-small cell lung cancer with afatinib                                  | oncological        | 260 392                                           |
| 60  | B.43.                  | Treatment of viral hepatitis B in beneficiaries after transplantations or in beneficiaries with lymphomas, treated with rituximab | non-oncological    | 208 648                                           |
| 61  | B.41.                  | Treatment of Prader-Willi syndrome                                                    | non-oncological    | 177 211                                           |
| 62  | B.38.                  | Treatment of dwarf children with chronic kidney failure                               | non-oncological    | 109 261                                           |
| 63  | B.64.                  | Treatment with growth hormone of dwarf children born too small in relation to pregnancy length (sga or iugr) | non-oncological    | 57 541                                            |
| 64  | B.21.                  | Treatment of severe familial hyperhomocysteinemia                                    | non-oncological    | 50 563                                            |
| 65  | B.75.                  | Treatment of active granulomatosis with polyangiitis (gpa) or microscopic polyangiitis (mpa) | non-oncological    | 34 340                                            |
| 66  | B.74.                  | Treatment of chronic thromboembolic pulmonary hypertension (cteph)                    | non-oncological    | 27 247                                            |
| 67  | B.73.                  | Treatment of neurogenic detrusor overactivity                                         | non-oncological    | 10 860                                            |
### REIMBURSEMENT BY DRUG PROGRAMME TYPE IN POLAND ESTIMATES TO 2016

*Appendix. 2. Reimbursement by drug programme type in Poland estimates to 2016, [USD].*

| Lp. | Number of drug program | Name of drug program                                                                 | Type                      | Values of reimbursement realised by the NHF, [USD] |
|-----|-------------------------|--------------------------------------------------------------------------------------|---------------------------|-----------------------------------------------|
| 1   | B.71.                   | Interferon-free treatment of chronic viral hepatitis C                                | non-oncological           | 116 043 837                                   |
| 2   | B.9.                    | Treatment of breast cancer                                                          | oncological               | 82 626 134                                    |
| 3   | B.29.                   | Treatment of multiple sclerosis                                                     | non-oncological           | 58 685 457                                    |
| 4   | B.10.                   | Treatment of renal cell carcinoma                                                   | oncological               | 34 788 764                                    |
| 5   | B.33.                   | Treatment of rheumatoid arthritis and aggressive juvenile idiopathic arthritis       | non-oncological           | 32 656 860                                    |
| 6   | B.54.                   | Lenalidomide in the treatment of refractory or relapsed multiple myeloma             | oncological               | 31 718 703                                    |
| 7   | B.4.                    | Treatment of advanced colorectal cancer                                             | oncological               | 31 532 468                                    |
| 8   | B.14.                   | Chronic myeloid leukemia                                                             | oncological               | 31 292 976                                    |
| 9   | B.3.                    | Treatment of gastrointestinal stromal tumours (GIST)                                 | oncological               | 23 254 701                                    |
| 10  | B.36.                   | Treatment of beneficiaries with severe active ankylosing spondylitis with TNF alfa inhibitors | non-oncological           | 19 035 602                                    |
| 11  | B.1.                    | Treatment of chronic viral hepatitis B                                              | non-oncological           | 18 998 771                                    |
| 12  | B.31.                   | Treatment of pulmonary arterial hypertension (PAH)                                  | non-oncological           | 17 609 026                                    |
| 13  | B.12.                   | Treatment of malignant lymphomas                                                    | oncological               | 17 211 421                                    |
| 14  | B.70.                   | Treatment of neovascular (exudative) form of age-related macular degeneration (AMD) | non-oncological           | 16 524 091                                    |
| 15  | B.46.                   | Treatment of multiple sclerosis after first line treatment failure or rapidly evolving severe multiple sclerosis | non-oncological           | 16 387 806                                    |
| Lp. | Number of drug program | Name of drug program | Type                  | Values of reimbursement realised by the NHF, [USD] |
|-----|------------------------|----------------------|-----------------------|--------------------------------------------------|
| 16  | B.23.                  | Treatment of Gaucher's disease | non-oncological | 12 247 283                                       |
| 17  | B.48.                  | Treatment of skin melanoma | oncological       | 12 086 553                                       |
| 18  | B.59.                  | Treatment of melanoma of skin or mucoosal melanoma | oncological | 11 564 784                                       |
| 19  | B.67.                  | Treatment with immunoglobulin transfusions in neurologic diseases | non-oncological | 10 933 407                                       |
| 20  | B.15.                  | Haemorrhages prevention in children with haemophilia A and B | non-oncological | 10 751 162                                       |
| 21  | B.56.                  | Treatment of castration-resistant prostate cancer | oncological | 9 582 437                                        |
| 22  | B.35.                  | Treatment of aggressive psoriatic arthritis | non-oncological | 9 240 550                                        |
| 23  | B.6.                   | Treatment of non-small cell lung cancer | oncological | 8 596 134                                        |
| 24  | B.22.                  | Treatment of Pompe disease | non-oncological | 8 261 478                                        |
| 25  | B.25.                  | Treatment of mucopolisacharosis type II (Hunter syndrome) | non-oncological | 8 119 287                                        |
| 26  | B.68.                  | Treatment of pulmonary arterial hypertension with sildenafil, epoprostenol and macitentan (PAH) | non-oncological | 7 314 161                                        |
| 27  | B.72.                  | Treatment of skin cancer with dabrafenib | oncological | 7 254 412                                        |
| 28  | B.32.                  | Treatment of Crohn’s disease (CD) | non-oncological | 7 151 874                                        |
| 29  | B.50.                  | Treatment of patients with advanced ovarian cancer | oncological | 6 341 163                                        |
| 30  | B.19.                  | Treatment of dwarf children with somatotropin pituitary insufficiency | non-oncological | 5 974 292                                        |
| 31  | B.44.                  | Treatment of severe ige-dependent allergic asthma with omalizumab | non-oncological | 5 785 056                                        |
| 32  | B.39.                  | Treatment of secondary hyperparathyroidism in haemodialysis patients | non-oncological | 5 719 989                                        |
| 33  | B.40.                  | Prevention of respiratory syncytial virus infections | non-oncological | 5 717 411                                        |
| 34  | B.62.                  | Treatment of primary immune deficiency (PID) in adult patients | non-oncological | 5 268 223                                        |
| 35  | B.2.                   | Treatment of chronic viral hepatitis C | non-oncological | 5 110 817                                        |
| 36  | B.8.                   | Treatment of soft tissue sarcomas | oncological | 4 140 049                                        |
| 37  | B.47.                  | Treatment of moderate and severe plaque psoriasis | non-oncological | 4 128 566                                        |
| 38  | B.5.                   | Treatment of hepatocellular carcinoma | oncological | 3 257 092                                        |
| 39  | B.24.                  | Treatment of Hurler disease | non-oncological | 3 044 951                                        |
| 40  | B.77.                  | Treatment of resistant and relapse lymphomas cd30+ | non-oncological | 2 789 296                                        |
| 41  | B.69.                  | Treatment with paricalcitol of secondary hyperparathyroidism in haemodialysis patients | non-oncological | 2 301 767                                        |
| Lp. | Number of drug program | Name of drug program                                                                 | Type             | Values of reimbursement realised by the NHF, [USD] |
|-----|------------------------|--------------------------------------------------------------------------------------|------------------|-----------------------------------------------|
| 42  | B.28.                  | Treatment of focal dystonia and hemifacial spasm                                     | non-oncological  | 2 273 806                                    |
| 43  | B.17.                  | Treatment of primary immunodeficiency in children                                    | non-oncological  | 2 072 179                                    |
| 44  | B.74.                  | Treatment of chronic thromboembolic pulmonary hypertension (cteph)                    | non-oncological  | 1 913 521                                    |
| 45  | B.58.                  | Treatment of advanced gastric cancer                                                  | oncological      | 1 726 773                                    |
| 46  | B.63.                  | Treatment of non-small cell lung cancer with afatinib                                 | oncological      | 1 345 313                                    |
| 47  | B.53.                  | Treatment of well-differentiated neuroendocrine pancreatic carcinoma                  | oncological      | 1 273 548                                    |
| 48  | B.65.                  | Treatment of Philadelphia chromosome-positive (Ph+) chronic acute lymphoblastic leukemia with dasatinib | oncological      | 1 108 758                                    |
| 49  | B.60.                  | Treatment of Gaucher’s disease type 1                                               | non-oncological  | 1 080 163                                    |
| 50  | B.42.                  | Treatment of dwarf children with Turner syndrome (TS)                                 | non-oncological  | 1 073 089                                    |
| 51  | B.20.                  | Treatment of dwarf children with severe primary igf-1 deficiency                      | non-oncological  | 1 064 833                                    |
| 52  | B.57.                  | Treatment of upper limb spasticity after stroke with botulinum toxin type A           | non-oncological  | 963 595                                      |
| 53  | B.76.                  | Treatment of tyrosinemia type 1 (ht-1)                                               | non-oncological  | 938 053                                      |
| 54  | B.26.                  | Treatment of mucopolysaccharidosis type IV (Maroteaux-Lamy syndrome)                  | non-oncological  | 925 455                                      |
| 55  | B.30.                  | Treatment of spasticity in cerebral palsy                                            | non-oncological  | 852 478                                      |
| 56  | B.37.                  | Treatment of anaemia in the course of chronic renal insufficiency                     | non-oncological  | 802 289                                      |
| 57  | B.66.                  | Treatment with bexarotene of mycosis fungoides or Sézary syndrome                    | non-oncological  | 764 950                                      |
| 58  | B.27.                  | Treatment of chronic lung infections in beneficiaries with mucoviscidosis             | non-oncological  | 743 424                                      |
| 59  | B.55.                  | Remission induction in ulcerative colitis                                             | non-oncological  | 704 633                                      |
| 60  | B.49.                  | Oral treatment of iron overload states in the body                                    | non-oncological  | 615 274                                      |
| 61  | B.52.                  | Treatment of squamous cell cancer of head and neck in combination with radiation therapy in locally advanced disease | oncological      | 520 243                                      |
| 62  | B.18.                  | Treatment of premature sexual maturation in children                                  | non-oncological  | 430 970                                      |
| 63  | B.75.                  | Treatment of active granulomatosis with polyangiitis (gpa) or microscopic polyangiitis (mpa) | non-oncological  | 429 808                                      |
| 64  | B.43.                  | Treatment of viral hepatitis B in beneficiaries after transplantations or in beneficiaries with lymphomas, treated with rituximab | non-oncological  | 218 676                                      |
| 65  | B.41.                  | Treatment of children with Prader-Willi syndrome                                      | non-oncological  | 188 621                                      |
| 66  | B.64.                  | Treatment with growth hormone of dwarf children born too small in relation to pregnancy length (sga lub) | non-oncological  | 174 771                                      |
## REIMBURSEMENT BY DRUG PROGRAMME TYPE IN POLAND ESTIMATES TO 2017

Appendix. 3. Reimbursement by drug programme type in Poland estimates to 2017, [USD].

| Lp. | Number of drug program | Name of drug program                                                                 | Type               | Values of reimbursement realised by the NHF, [USD] |
|-----|------------------------|--------------------------------------------------------------------------------------|--------------------|---------------------------------------------------|
| 1   | B.9.                   | Treatment of breast cancer                                                           | oncological        | 118 276 084                                      |
| 2   | B.71.                  | Interferon-free treatment of chronic viral hepatitis C                               | non-oncological    | 109 178 658                                      |
| 3   | B.29.                  | Treatment of multiple sclerosis                                                      | non-oncological    | 66 378 300                                       |
| 4   | B.54.                  | Treatment of refractory or relapsed multiple myeloma                                 | oncological        | 36 985 168                                       |
| 5   | B.10.                  | Treatment of renal cell carcinoma                                                    | oncological        | 35 019 759                                       |
| 6   | B.4.                   | Treatment of advanced colorectal cancer                                              | oncological        | 34 302 745                                       |
| Lp. | Number of drug program | Name of drug program                                                                 | Type          | Values of reimbursement realised by the NHF, [USD] |
|-----|------------------------|--------------------------------------------------------------------------------------|---------------|-----------------------------------------------|
| 7   | B.33.                  | Treatment of rheumatoid arthritis and aggressive juvenile idiopathic arthritis        | non-oncological | 33 284 884                                   |
| 8   | B.14.                  | Treatment of chronic myeloid leukemia                                               | oncological   | 28 998 737                                   |
| 9   | B.59.                  | Treatment of skin or mucosal melanoma                                              | oncological   | 23 710 717                                   |
| 10  | B.3.                   | Treatment of gastrointestinal stromal tumours (GIST)                                | oncological   | 21 657 287                                   |
| 11  | B.36.                  | Treatment of beneficiaries with severe active ankylosing spondylitis with TNF alfa inhibitors | non-oncological | 19 046 874                                   |
| 12  | B.46.                  | Treatment of multiple sclerosis after first line treatment failure or rapidly evolving severe multiple sclerosis | non-oncological | 18 823 968                                   |
| 13  | B.31.                  | Treatment of pulmonary arterial hypertension (PAH)                                  | non-oncological | 18 700 871                                   |
| 14  | B.70.                  | Treatment of neovascular (exudative) form of age-related macular degeneration (AMD) | non-oncological | 18 103 475                                   |
| 15  | B.12.                  | Treatment of malignant lymphomas                                                    | oncological   | 16 949 679                                   |
| 16  | B.1.                   | Treatment of chronic viral hepatitis B                                              | non-oncological | 16 726 079                                   |
| 17  | B.67.                  | Treatment with immunoglobulin transfusions in neurologic diseases                  | non-oncological | 14 663 919                                   |
| 18  | B.72.                  | Treatment of melanoma with combination therapy with dabrafenib and trametinib       | oncological   | 14 174 447                                   |
| 19  | B.56.                  | Treatment of castration-resistant prostate cancer                                   | oncological   | 13 387 547                                   |
| 20  | B.23.                  | Treatment of Gaucher’s disease type 1                                               | non-oncological | 13 357 659                                   |
| 21  | B.15.                  | Haemorrhages prevention in children with haemophilia A and B                         | non-oncological | 11 488 207                                   |
| 22  | B.68.                  | Treatment of pulmonary arterial hypertension with sildenafil, epoprostenol and macitentan (PAH) | non-oncological | 10 770 605                                   |
| 23  | B.35.                  | Treatment of aggressive psoriatic arthritis                                         | non-oncological | 10 314 324                                   |
| 24  | B.22.                  | Treatment of Pompe disease                                                          | non-oncological | 9 579 385                                    |
| 25  | B.77.                  | Treatment of resistant and relapse lymphomas cd30+                                  | oncological   | 9 355 582                                    |
| Lp. | Number of drug program | Name of drug program                                                                 | Type               | Values of reimbursement realised by the NHF, [USD] |
|-----|------------------------|--------------------------------------------------------------------------------------|--------------------|---------------------------------------------------|
| 26  | B.32.                  | Treatment of Crohn’s disease (CD)                                                   | non-oncological    | 8 454 469                                        |
| 27  | B.48.                  | Treatment of skin melanoma                                                           | oncological        | 8 210 473                                        |
| 28  | B.6.                   | Treatment of non-small cell lung cancer                                              | oncological        | 7 614 113                                        |
| 29  | B.50.                  | Treatment of patients with advanced ovarian cancer                                   | oncological        | 7 409 942                                        |
| 30  | B.44.                  | Treatment of severe ige-dependent allergic asthma with omalizumab                    | non-oncological    | 6 782 211                                        |
| 31  | B.40.                  | Prevention of respiratory syncytial virus infections                                | non-oncological    | 6 562 042                                        |
| 32  | B.25.                  | Treatment of mucopolisacharosis type II (Hunter syndrome)                            | non-oncological    | 6 506 251                                        |
| 33  | B.19.                  | Treatment of dwarf children with somatotropin pituitary insufficiency                | non-oncological    | 6 401 367                                        |
| 34  | B.62.                  | Treatment of primary immunodeficiency in adults                                     | non-oncological    | 5 757 874                                        |
| 35  | B.47.                  | Treatment of moderate and severe plaque psoriasis                                   | non-oncological    | 5 223 983                                        |
| 36  | B.8.                   | Treatment of soft tissue sarcomas                                                    | oncological        | 4 288 962                                        |
| 37  | B.39.                  | Treatment of secondary hyperparathyroidism in haemodialysis patients                | non-oncological    | 3 950 574                                        |
| 38  | B.74.                  | Treatment of chronic thromboembolic pulmonary hypertension (cteph)                  | non-oncological    | 3 298 036                                        |
| 39  | B.5.                   | Treatment of hepatocellular carcinoma                                               | oncological        | 3 283 906                                        |
| 40  | B.79.                  | Treatment of chronic lymphocytic leukemia with obinutuzumab                           | oncological        | 3 071 287                                        |
| 41  | B.24.                  | Treatment of Hurler disease                                                          | non-oncological    | 2 935 966                                        |
| 42  | B.63.                  | Treatment of non-small cell lung cancer with afatinib and nintedanib                 | oncological        | 2 468 621                                        |
| 43  | B.28.                  | Treatment of focal dystonia and hemifacial spasm                                    | non-oncological    | 2 392 192                                        |
| 44  | B.81.                  | Treatment of primary mielofibrosis and secondary mielofibrosis in the course of polycyemia and thrombocytosis | oncological        | 2 382 702                                        |
| Lp. | Number of drug program | Name of drug program                                                                 | Type           | Values of reimbursement realised by the NHF, [USD] |
|-----|------------------------|--------------------------------------------------------------------------------------|----------------|-----------------------------------------------|
| 45  | B.80.                  | Maintenance therapy with olaparib of patients with relapsed platinum-sensitive advanced ovarian cancer, fallopian tube cancer or primary peritoneal cancer | oncological    | 2 329 554                                    |
| 46  | B.17.                  | Treatment of primary immunodeficiency in children                                   | non-oncological| 2 290 480                                    |
| 47  | B.2.                   | Treatment of chronic viral hepatitis c                                              | non-oncological| 2 198 818                                    |
| 48  | B.58.                  | Treatment of advanced gastric cancer                                               | oncological    | 2 097 652                                    |
| 49  | B.55.                  | Treatment of patients with colitis ulcerosis                                       | non-oncological| 1 837 395                                    |
| 50  | B.53.                  | Treatment of well-differentiated neuroendocrine pancreatic carcinoma                | oncological    | 1 766 397                                    |
| 51  | B.26.                  | Treatment of mucopolysaccharidosis type iv (maroteaux-lamy syndrome)                | non-oncological| 1 728 893                                    |
| 52  | B.87.                  | Treatment of idiopathic pulmonary fibrosis                                           | non-oncological| 1 671 679                                    |
| 53  | B.84.                  | Lenalidomid for the treatment of patients with anemia depending on transformations in the course of myelodysplastic assemblies with low or indirect risk, risk associated with cytogenetic irregularity with 5q deletion | oncological    | 1 586 077                                    |
| 54  | B.69.                  | Treatment with paricalcitol of secondary hyperparathyroidism in haemodialysis patients | non-oncological| 1 529 137                                    |
| 55  | B.76.                  | Treatment of tyrosinemia type 1 (ht-1)                                              | non-oncological| 1 499 983                                    |
| 56  | B.78.                  | Treatment of primary immune deficiencies in adult patients with normal human immunoglobulin administered with human recombined hyaluronidase | non-oncological| 1 389 103                                    |
| 57  | B.60.                  | Treatment of gaucher’s disease type 1                                               | non-oncological| 1 244 807                                    |
| 58  | B.42.                  | Treatment of dwarf children with turner syndrome (ts)                               | non-oncological| 1 032 587                                    |
| 59  | B.20.                  | Treatment of dwarf children with severe primary igf-1 deficiency                    | non-oncological| 887 751                                      |
| 60  | B.27.                  | Treatment of chronic lung infections in beneficiaries with mucoviscidosis           | non-oncological| 832 382                                      |
| 61  | B.65.                  | Treatment of acute lymphoblastic leukemia                                            | oncological    | 826 749                                      |
| 62  | B.30.                  | Treatment of spasticity in cerebral palsy                                           | non-oncological| 810 558                                      |
| Lp. | Number of drug program | Name of drug program                                                                 | Type            | Values of reimbursement realised by the NHF, [USD] |
|-----|------------------------|--------------------------------------------------------------------------------------|-----------------|---------------------------------------------------|
| 63  | B.37.                  | Treatment of anaemia in the course of chronic renal insufficiency                    | non-oncological | 778 431                                           |
| 64  | B.57.                  | Treatment of upper limb spasticity after stroke with botulinum toxin type a         | non-oncological | 762 256                                           |
| 65  | B.66.                  | Treatment with bexarotene of mycosis fungoides or sézary syndrome                   | oncological     | 736 061                                           |
| 66  | B.88.                  | Treatment of patients with advanced basocellular skin cancer wismodegib             | oncological     | 609 818                                           |
| 67  | B.85.                  | Treatment of patients with metastatic pancreatic adenocarcinoma                    | oncological     | 603 611                                           |
| 68  | B.18.                  | Treatment of premature sexual maturation in children                                | non-oncological | 478 466                                           |
| 69  | B.75.                  | Treatment of active granulomatosis with polyangiitis (gpa) or microscopic polyangiitis (mpa) | non-oncological | 475 941                                           |
| 70  | B.64.                  | Treatment with growth hormone of dwarf children born too small in relation to pregnancy length (sga or iugr) | non-oncological | 409 770                                           |
| 71  | B.49.                  | Oral treatment of iron overload states in the body                                  | non-oncological | 372 776                                           |
| 72  | B.52.                  | Treatment of squamous cell cancer of head and neck                                  | oncological     | 364 229                                           |
| 73  | B.41.                  | Treatment of prader-willi syndrome                                                 | non-oncological | 207 472                                           |
| 74  | B.43.                  | Treatment of viral hepatitis b in beneficiaries after transplantations or in beneficiaries with lymphomas, treated with rituximab | non-oncological | 186 964                                           |
| 75  | B.38.                  | Treatment of dwarf children with chronic kidney failure                             | non-oncological | 114 339                                           |
| 76  | B.83.                  | Treatment of lower limb spasticity after stroke with botulinum toxin type a        | non-oncological | 89 713                                            |
| 77  | B.82.                  | Treatment of certolizumab pegol patients with heavy, active form of axial spondyloarthropathy (spa) without radiographic changes | non-oncological | 69 770                                            |
| 78  | B.21.                  | Treatment of severe familial hyperhomocysteinemia                                  | non-oncological | 63 785                                            |
| 79  | B.89.                  | Treatment with everolimus of patients with sclerosis tuberosa non-qualifying for operative treatments with subependymal giant cells (sega) | oncological     | 52 467                                            |
| 80  | B.61.                  | Treatment of nephropathic juvenile cystinosis                                       | non-oncological | 39 084                                            |
| 81  | B.86.                  | Treatment of congenituated auto-inflammatory assemblies                              | non-oncological | 36 356                                            |
| 82  | B.90.                  | Treatment of motor disorders in the course of advanced parkinson's disease         | non-oncological | 17 303                                            |
### REIMBURSEMENT BY DRUG PROGRAMME TYPE IN POLAND ESTIMATES TO 2018

Source: own elaboration, NHF data.

#### Appendix 4. Reimbursement by drug programme type in Poland estimates to 2018, [USD].

| Lp. | Number of drug program | Name of drug program                                           | Type               | Values of reimbursement realised by the NHF, [USD] |
|-----|------------------------|-----------------------------------------------------------------|--------------------|-----------------------------------------------|
| 83  | B.73.                  | Treatment of neurogenic detrusor overactivity                   | non-oncological    | 13 543                                        |

1 B.9. Treatment of breast cancer
2 B.29. Treatment of multiple sclerosis
3 B.71. Interferon-free treatment of chronic viral hepatitis C
4 B.4. Treatment of advanced colorectal cancer
5 B.54. Treatment of refractory or relapsed multiple myeloma
6 B.10. Treatment of renal cell carcinoma
7 B.33. Treatment of rheumatoid arthritis and aggressive juvenile idiopathic arthritis
8 B.59. Treatment of skin or mucosal melanoma
9 B.14. Treatment of chronic myeloid leukemia
10 B.31. Treatment of pulmonary arterial hypertension (PAH)
11 B.56. Treatment of castration-resistant prostate cancer
12 B.3. Treatment of gastrointestinal stromal tumours (GIST)
| Lp. | Number of drug program | Name of drug program                                                                 | Type                     | Values of reimbursement realised by the NHF, USD |
|-----|------------------------|--------------------------------------------------------------------------------------|--------------------------|-----------------------------------------------|
| 13  | B.70.                  | Treatment of neovascular (exudative) form of age-related macular degeneration (AMD)   | non-oncological          | 21 045 965                                   |
| 14  | B.46.                  | Treatment of multiple sclerosis after first line treatment failure or rapidly evolving severe multiple sclerosis | non-oncological          | 20 021 314                                   |
| 15  | B.36.                  | Treatment of beneficiaries with severe active ankylosing spondylitis with TNF alfa inhibitors | non-oncological          | 19 835 842                                   |
| 16  | B.72.                  | Treatment of melanoma with combination therapy with dabrafenib and trametinib        | oncological              | 18 463 676                                   |
| 17  | B.6.                   | Treatment of non-small cell lung cancer                                              | oncological              | 17 049 924                                   |
| 18  | B.12.                  | Treatment of malignant lymphomas                                                    | oncological              | 15 579 222                                   |
| 19  | B.67.                  | Treatment with immunoglobulin transfusions in neurologic diseases                   | non-oncological          | 15 333 074                                   |
| 20  | B.23.                  | Treatment of Gaucher’s disease                                                       | non-oncological          | 14 673 701                                   |
| 21  | B.35.                  | Treatment of aggressive psoriatic arthritis                                          | non-oncological          | 11 102 138                                   |
| 22  | B.68.                  | Treatment of pulmonary arterial hypertension with sildenafil, epoprostenol and macitentan (pah) | non-oncological          | 10 909 480                                   |
| 23  | B.32.                  | Treatment of crohn’s disease (cd)                                                    | non-oncological          | 9 712 364                                    |
| 24  | B.81.                  | Treatment of primary mielofibrosis and secondary mielofibrosis in the course of polycythemia and thrombocythisis | oncological              | 9 323 293                                    |
| 25  | B.87.                  | Treatment of idiopathic pulmonary fibrosis                                           | non-oncological          | 9 265 419                                    |
| 26  | B.15.                  | Haemorrhages prevention in children with haemophilia a and b                          | non-oncological          | 8 739 265                                    |
| 27  | B.1.                   | Treatment of chronic viral hepatitis b                                               | non-oncological          | 8 684 694                                    |
| 28  | B.48.                  | Treatment of skin melanoma                                                           | oncological              | 8 626 239                                    |
| 29  | B.22.                  | Treatment of pompe disease                                                           | non-oncological          | 8 567 666                                    |
| 30  | B.77.                  | Treatment of resistant and relapse lymphomas cd30+                                   | oncological              | 7 935 812                                    |
| 31  | B.80.                  | Maintenance therapy with olaparib of patients with relapsed platinum-sensitive advanced ovarian cancer. | oncological              | 7 755 700                                    |
| Lp. | Number of drug program | Name of drug program | Type | Values of reimbursement realised by the NHF, [USD] |
|-----|------------------------|----------------------|------|----------------------------------------|
| 32  | B.50.                  | Treatment of patients with advanced ovarian cancer | oncological | 7 391 638 |
| 33  | B.40.                  | Prevention of respiratory syncytial virus infections | non-oncological | 7 306 999 |
| 34  | B.44.                  | Treatment of severe ige-dependent allergic asthma with omalizumab | non-oncological | 6 977 968 |
| 35  | B.19.                  | Treatment of dwarf children with somatotropin pituitary insufficiency | non-oncological | 6 869 004 |
| 36  | B.25.                  | Treatment of mucopolisacharosis type ii (hunter syndrome) | non-oncological | 6 678 216 |
| 37  | B.47.                  | Treatment of aggressive psoriatic arthritis | non-oncological | 6 112 470 |
| 38  | B.62.                  | Treatment of primary immunodeficiency in adults | non-oncological | 5 549 987 |
| 39  | B.79.                  | Treatment of chronic lymphocytic leukemia with obinutuzumab | oncological | 5 514 203 |
| 40  | B.74.                  | Treatment of chronic thromboembolic pulmonary hypertension (cteph) | non-oncological | 4 589 063 |
| 41  | B.84.                  | Lenalidomid for the treatment of patients with anemia depending on transformations in the course of myelodysplastic assemblies with low or indirect risk, risk associated with cytogenetic irregularity with 5q deletion | oncological | 3 914 369 |
| 42  | B.92.                  | Ibrutynib in the treatment of patients with chronic lymphocytic leukemia | oncological | 3 768 442 |
| 43  | B.8.                   | Treatment of soft tissue sarcomas | oncological | 3 478 333 |
| 44  | B.88.                  | Treatment of patients with advanced basocellular skin cancer wismodegib | oncological | 3 438 567 |
| 45  | B.39.                  | Treatment of secondary hyperparathyroidism in haemodialysis patients | non-oncological | 3 218 567 |
| 46  | B.63.                  | Treatment of non-small cell lung cancer with afatinib and nintedanib | oncological | 3 076 843 |
| 47  | B.95.                  | Treatment of atypical hemolytic-uremic syndrome (ahu) | non-oncological | 3 048 972 |
| 48  | B.96.                  | Treatment of paroxysmal nocturnal hemoglobinuria | non-oncological | 3 022 699 |
| 49  | B.5.                   | Treatment of hepatocellular carcinoma | oncological | 2 855 103 |
| Lp. | Number of drug program | Name of drug program                                                                 | Type              | Values of reimbursement realised by the NHF, [USD] |
|-----|------------------------|--------------------------------------------------------------------------------------|-------------------|---------------------------------------------------|
| 50  | B.78.                  | Treatment of primary immune deficiencies in adult patients with normal human immunoglobulin administered with human recombinant hyaluronidase | non-oncological   | 2 852 819                                        |
| 51  | B.24.                  | Treatment of Hurler disease                                                          | non-oncological   | 2 836 066                                        |
| 52  | B.17.                  | Treatment of primary immunodeficiency in children                                    | non-oncological   | 2 832 343                                        |
| 53  | B.55.                  | Treatment of patients with ulcerative colitis                                        | non-oncological   | 2 781 703                                        |
| 54  | B.28.                  | Treatment of focal dystonia and hemifacial spasm                                    | non-oncological   | 2 578 618                                        |
| 55  | B.85.                  | Treatment of patients with metastatic pancreatic adenocarcinoma                     | oncological       | 2 329 798                                        |
| 56  | B.58.                  | Treatment of advanced gastric cancer                                                 | oncological       | 2 262 861                                        |
| 57  | B.53.                  | Treatment of well-differentiated neuroendocrine pancreatic carcinoma                 | oncological       | 1 731 430                                        |
| 58  | B.69.                  | Treatment of secondary hyperparathyroidism in haemodialysis patients                 | non-oncological   | 1 513 055                                        |
| 59  | B.60.                  | Treatment of Gaucher's disease type I                                                | non-oncological   | 1 422 153                                        |
| 60  | B.26.                  | Treatment of mucopolysaccharidosis type IV (Maroteaux-Lamy syndrome)                  | non-oncological   | 1 334 243                                        |
| 61  | B.76.                  | Treatment of tyrosinemia type 1 (HT-1)                                               | non-oncological   | 1 271 372                                        |
| 62  | B.20.                  | Treatment of dwarf children with severe primary IGF-1 deficiency                     | non-oncological   | 1 135 330                                        |
| 63  | B.42.                  | Treatment of dwarf children with Turner syndrome (TS)                                | non-oncological   | 1 059 483                                        |
| 64  | B.2.                   | Treatment of chronic viral hepatitis C                                               | non-oncological   | 1 057 169                                        |
| 65  | B.27.                  | Treatment of chronic lung infections in beneficiaries with mucoviscidosis            | non-oncological   | 885 183                                          |
| 66  | B.57.                  | Treatment of upper limb spasticity after stroke with botulinum toxin type a         | non-oncological   | 867 516                                          |
| 67  | B.65.                  | Treatment of acute lymphoblastic leukemia                                             | oncological       | 849 380                                          |
| 68  | B.30.                  | Treatment of spasticity in cerebral palsy                                            | non-oncological   | 786 463                                          |
| Lp. | Number of drug program | Name of drug program                                                                 | Type          | Values of reimbursement realised by the NHF, [USD] |
|-----|------------------------|--------------------------------------------------------------------------------------|---------------|---------------------------------------------------|
| 69  | B.89.                  | Treatment with everolimus of patients with sclerosis tuberosa non-qualifying for operative treatments with subependymal giant cells (sega) | oncological   | 772 851                                           |
| 70  | B.64.                  | Treatment with growth hormone of dwarf children born too small in relation to pregnancy length (sga or iugr) | non-oncological | 749 597                                           |
| 71  | B.37.                  | Treatment of anaemia in the course of chronic renal insufficiency                    | non-oncological | 731 097                                           |
| 72  | B.66.                  | Treatment with beksarotene of mycosis fungoides or sézary syndrome                   | oncological   | 718 945                                           |
| 73  | B.90.                  | Treatment of motor disorders in the course of advanced parkinson's disease           | non-oncological | 611 303                                           |
| 74  | B.75.                  | Treatment of active granulomatosis with polyangiitis (gpa) or microscopic polyangiitis (mpa) | non-oncological | 523 936                                           |
| 75  | B.82.                  | Treatment of certolizumab pegol patients with heavy, active form of axial spondyloartropathy without radiographic changes | non-oncological | 509 266                                           |
| 76  | B.18.                  | Treatment of premature sexual maturation in children                                  | non-oncological | 507 553                                           |
| 77  | B.83.                  | Treatment of lower limb spasticity after stroke with botulinum toxin type a          | non-oncological | 450 700                                           |
| 78  | B.93.                  | Pixsantron for the treatment of malignant lymphoma                                    | oncological   | 427 712                                           |
| 79  | B.97.                  | Treatment of adults with idiopathic thrombocytopenic purpura                          | non-oncological | 352 674                                           |
| 80  | B.100.                 | Treatment of resistant and recurrental form of hodgkin's classic lymphoma using niwolumab | oncological   | 259 071                                           |
| 81  | B.86.                  | Treatment of congenitated auto-inflammatory disorders                                 | non-oncological | 243 684                                           |
| 82  | B.52.                  | Treatment of squamous cell cancer of head and neck                                    | oncological   | 224 321                                           |
| 83  | B.41.                  | Treatment of prader - willi syndrome                                                  | non-oncological | 220 229                                           |
| 84  | B.49.                  | Oral treatment of iron overload states in the body                                    | non-oncological | 219 311                                           |
| 85  | B.98.                  | Treatment of pediatric patients with chronic primary immuno thrombocytopenia          | non-oncological | 215 894                                           |
| 86  | B.43.                  | Treatment of viral hepatitis B in beneficiaries after transplantations or in beneficiaries with lymphomas, treated with rituximab | non-oncological | 170 902                                           |
| 87  | B.91.                  | Treatment of severe immunoresistant pemphigus with rituximab                          | non-oncological | 144 466                                           |
| 88  | B.99.                  | Treatment of acromegal with passyothide                                              | non-oncological | 103 823                                           |
| 89  | B.38.                  | Treatment of dwarf children with chronic kidney failure                               | non-oncological | 102 225                                           |
| Lp. | Number of drug program | Name of drug program                                      | Type               | Values of reimbursement realised by the NHF, [USD] |
|-----|------------------------|-----------------------------------------------------------|--------------------|---------------------------------------------------|
| 90  | B.21.                  | Treatment of severe familial hyperhomocysteinemia         | non-oncological    | 54 227                                            |
| 91  | B.61.                  | Treatment of nephropathic juvenile cystinosis             | non-oncological    | 18 842                                            |
| 92  | B.73.                  | Treatment of neurogenic detrusor overactivity             | non-oncological    | 9 815                                             |

Source: own elaboration, NHF data.